Science Explorer Back to mapMap
Discussion
Researcher · Gladstone Institutes · United States

Michael Alexanian

Michael Alexanian publishes mostly in Molecular Biology, Cardiology and Cardiovascular Medicine and Oncology, on topics such as Congenital heart defects research, Protein Degradation and Inhibitors and Cardiac Fibrosis and Remodeling.

ORCID 0000-0001-6224-6354 OpenAlex
World rank
#714,949
of 7,710,434 ranked researchers
Rank in United States
#241,229
of 1,627,098
Works
43
Citations
2.3k
Citations per work
54.0
h-index
17
i10-index 23Top 42% in Molecular Biology
Michael Alexanian

What does Michael Alexanian research?

Michael Alexanian's work is mostly in Biochemistry, Genetics and Molecular Biology (66%), Medicine (25%).

Life Sciences: 28 works · 65.8% of their workBiochemistry, Genetics and Molecular Biology: 28 works · 65.8% of their workMolecular Biology: 25 works · 59.3% of their workCancer Research: 3 works · 6.5% of their workHealth Sciences: 11 works · 25.3% of their workMedicine: 11 works · 25.3% of their workCardiology and Cardiovascular Medicine: 5 works · 10.6% of their workOncology: 3 works · 7.3% of their workEpidemiology: 2 works · 4.1% of their workSurgery: 1 works · 3.3% of their workEverything else: 4 works · 8.9% of their workTHEIR WORKMichael Alexanian43works
Life Sciences66%Health Sciences25%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology2865.8%
    1. Medicine1125.3%
  3. Everything else48.9%
  1. 1Molecular Biology59% of their works
  2. 2Cardiology and Cardiovascular Medicine11% of their works
  3. 3Oncology7% of their works
  4. 4Cancer Research6% of their works
  5. 5Epidemiology4% of their works
  6. 6Surgery3% of their works

Research topics

Which keywords describe Michael Alexanian's research?

The keywords of their largest research topics: Transcriptional Regulation, Cancer Progression, BET Bromodomains, Cardiomyocyte Renewal, Heart Regeneration, PROTACs, Cardiac Remodeling and Inflammatory Response.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 18 words, with their numbers
  1. Transcriptional Regulation202 topics
  2. Cancer Progression172 topics
  3. BET Bromodomains121 topic
  4. Cardiomyocyte Renewal121 topic
  5. Heart Regeneration121 topic
  6. PROTACs121 topic
  7. Cardiac Remodeling101 topic
  8. Inflammatory Response101 topic
  9. Fibroblast Activation Protein91 topic
  10. RNA methylation91 topic
  11. Tumor Microenvironment91 topic
  12. m6A-seq91 topic
  13. Calcineurin81 topic
  14. Cancer81 topic
  15. Long Noncoding RNAs81 topic
  16. NFAT81 topic
  17. Alternative Splicing61 topic
  18. RNA-Binding Proteins61 topic

Where does Michael Alexanian work?

Michael Alexanian's main affiliation in the publication record is Gladstone Institutes, United States.

How many publications and citations does Michael Alexanian have?

OpenAlex counts 43 works and 2,321 citations for Michael Alexanian, an h-index of 17, ranking #714,949 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Michael Alexanian. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.